Literature DB >> 27377825

The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.

Muhammad Kashif Riaz1, Susan Bal1, Trisha Wise-Draper2.   

Abstract

Metastatic cancer remains a devastating disease that threatens to disrupt entire family structures creating economic and psychosocial stress. Fortunately, great strides have resulted in improved therapies over the years but at a huge social-economic cost. The economic burden has risen greatly and carries with it new ethical concerns when deciding treatment. Here, we discuss the financial and ethical challenges that oncologists and their patients face in the era of novel treatment strategies. J. Surg. Oncol. 2016;114:323-328.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemotherapy; cost effectiveness; metastatic cancer

Mesh：

Year:  2016        PMID： 27377825      PMCID： PMC5867536          DOI： 10.1002/jso.24333

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  34 in total

1.  Legislating against use of cost-effectiveness information.

Authors:  Peter J Neumann; Milton C Weinstein
Journal:  N Engl J Med       Date:  2010-10-14       Impact factor: 91.245

2.  Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Authors:  Jan B Vermorken; Jan Stöhlmacher-Williams; Irina Davidenko; Lisa Licitra; Eric Winquist; Cristian Villanueva; Paolo Foa; Sylvie Rottey; Krzysztof Skladowski; Makoto Tahara; Vasant R Pai; Sandrine Faivre; Cesar R Blajman; Arlene A Forastiere; Brian N Stein; Kelly S Oliner; Zhiying Pan; Bruce A Bach
Journal:  Lancet Oncol       Date:  2013-06-06       Impact factor: 41.316

3.  Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Authors:  Emily Ruden; David A Reardon; April D Coan; James E Herndon; Whitney E Hornsby; Miranda West; Diane R Fels; Annick Desjardins; James J Vredenburgh; Emily Waner; Allan H Friedman; Henry S Friedman; Katherine B Peters; Lee W Jones
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

4.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:  Ayalew Tefferi; Hagop Kantarjian; S Vincent Rajkumar; Lawrence H Baker; Jan L Abkowitz; John W Adamson; Ranjana Hira Advani; James Allison; Karen H Antman; Robert C Bast; John M Bennett; Edward J Benz; Nancy Berliner; Joseph Bertino; Ravi Bhatia; Smita Bhatia; Deepa Bhojwani; Charles D Blanke; Clara D Bloomfield; Linda Bosserman; Hal E Broxmeyer; John C Byrd; Fernando Cabanillas; George Peter Canellos; Bruce A Chabner; Asher Chanan-Khan; Bruce Cheson; Bayard Clarkson; Susan L Cohn; Gerardo Colon-Otero; Jorge Cortes; Steven Coutre; Massimo Cristofanilli; Walter J Curran; George Q Daley; Daniel J DeAngelo; H Joachim Deeg; Lawrence H Einhorn; Harry P Erba; Francisco J Esteva; Elihu Estey; Isaiah J Fidler; James Foran; Stephen Forman; Emil Freireich; Charles Fuchs; James N George; Morie A Gertz; Sergio Giralt; Harvey Golomb; Peter Greenberg; Jordan Gutterman; Robert I Handin; Samuel Hellman; Paulo Marcelo Hoff; Ronald Hoffman; Waun Ki Hong; Mary Horowitz; Gabriel N Hortobagyi; Clifford Hudis; Jean Pierre Issa; Bruce Evan Johnson; Philip W Kantoff; Kenneth Kaushansky; David Khayat; Fadlo R Khuri; Thomas J Kipps; Margaret Kripke; Robert A Kyle; Richard A Larson; Theodore S Lawrence; Ross Levine; Michael P Link; Scott M Lippman; Sagar Lonial; Gary H Lyman; Maurie Markman; John Mendelsohn; Neal J Meropol; Yoav Messinger; Therese M Mulvey; Susan O'Brien; Roman Perez-Soler; Raphael Pollock; Josef Prchal; Oliver Press; Jerald Radich; Kanti Rai; Saul A Rosenberg; Jacob M Rowe; Hope Rugo; Carolyn D Runowicz; Brenda M Sandmaier; Alan Saven; Andrew I Schafer; Charles Schiffer; Mikkael A Sekeres; Richard T Silver; Lillian L Siu; David P Steensma; F Marc Stewart; Wendy Stock; Richard Stone; Rainer Storb; Louise C Strong; Martin S Tallman; Michael Thompson; Naoto T Ueno; Richard A Van Etten; Julie M Vose; Peter H Wiernik; Eric P Winer; Anas Younes; Andrew D Zelenetz; Charles A LeMaistre
Journal:  Mayo Clin Proc       Date:  2015-07-23       Impact factor: 7.616

5.  Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Authors:  Daniel A Goldstein; Bilal B Ahmad; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.

Authors:  Janice K Kiecolt-Glaser; Jeanette M Bennett; Rebecca Andridge; Juan Peng; Charles L Shapiro; William B Malarkey; Charles F Emery; Rachel Layman; Ewa E Mrozek; Ronald Glaser
Journal:  J Clin Oncol       Date:  2014-01-27       Impact factor: 44.544

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.

Authors:  John W Tumeh; Pareen J Shenoy; Susan G Moore; John Kauh; Christopher Flowers
Journal:  Am J Clin Oncol       Date:  2009-02       Impact factor: 2.339

9.  Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.

Authors:  Crystal T Pike; Howard G Birnbaum; Catherine E Muehlenbein; Gerhardt M Pohl; Ronald B Natale
Journal:  Chemother Res Pract       Date:  2012-03-14

10.  Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.

Authors:  Patti Curl; Igor Vujic; Laura J van 't Veer; Susana Ortiz-Urda; James G Kahn
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240
View more
  1 in total

1.  A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.

Authors:  Clare T Butler; Alison L Reynolds; Miriam Tosetto; Eugene T Dillon; Patrick J Guiry; Gerard Cagney; Jacintha O'Sullivan; Breandán N Kennedy
Journal:  J Biol Chem       Date:  2016-12-29       Impact factor: 5.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.